"iDoctor – Medical Blog"

ORLANDO (MedPage Today) — Maintenance therapy with pemetrexed (Alimta) added about three months to overall survival in patients with advanced, non-small cell lung cancer (NSCLC) who had not progressed on platinum-based treatment, researchers here reported.

This entry was posted on Thursday, June 4th, 2009 at 8:29 am and is filed under Health news. You can follow any responses to this entry through the RSS 2.0 feed. You can skip to the end and leave a response. Pinging is currently not allowed.